Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Daewon Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, with a strong presence in the South Korean market and expanding operations in Southeast Asia. The company is distinguished by its extensive product portfolio, including over 300 generic drugs and a growing pipeline of specialty medications, which positions it favorably against competitors in a highly regulated industry.
Daewon generates revenue primarily through the sale of generic pharmaceuticals, leveraging its established relationships with hospitals and pharmacies. The company benefits from economies of scale in production, allowing it to maintain competitive pricing while investing in R&D for specialty drugs, which typically command higher margins.
Regulatory approvals for new generic drugs
Market share changes in the South Korean pharmaceutical market
Pricing pressures from government healthcare policies
Partnerships or collaborations for drug development
Regulatory changes affecting drug pricing and approval processes
Technological disruptions in drug manufacturing and delivery
Increased competition from domestic and international generic manufacturers
Potential for price wars in the generic drug market
Negative net margin indicating potential liquidity issues
High capital expenditures impacting cash flow stability
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending and healthcare budgets can impact demand for non-essential medications.
Interest rates affect Daewon's financing costs for R&D and capital expenditures, with higher rates potentially constraining investment in new drug development.
minimal - The company has a manageable debt-to-equity ratio of 0.70, indicating limited reliance on external financing.
value - Investors may be drawn to the low valuation metrics, particularly the price-to-sales ratio of 0.3x, indicating potential for recovery.
high - The stock has experienced significant volatility, with a one-year return of -40.6%, reflecting market uncertainty.
